Jayesh Thaker (@Fino_Sphere) profile picture

Investor since 3 decades, Reader, Trekker, Learner. Sharing info & insights to/from financially aware community. Microbiology, Law, MBA Finance, still learning.

Ahmedabad
Joined December 2017
Photo by Jayesh Thaker (@Fino_Sphere)Photo by Jayesh Thaker (@Fino_Sphere)Photo by Jayesh Thaker (@Fino_Sphere)Photo by Jayesh Thaker (@Fino_Sphere)Photo by Jayesh Thaker (@Fino_Sphere)Photo by Jayesh Thaker (@Fino_Sphere)Photo by Jayesh Thaker (@Fino_Sphere)Photo by Jayesh Thaker (@Fino_Sphere)Photo by Jayesh Thaker (@Fino_Sphere)Photo by Jayesh Thaker (@Fino_Sphere)
Jayesh Thaker retweeted
Almost 1 Lk Cr FII Buying ₹97,000 Cr Buying in Two Weeks 18th Nov: ₹5867 cr 🟩 17th Nov: ₹4195 cr 🟩 16th Nov: ₹4864 cr 🟩 13th Nov: ₹5253 cr 🟩 12th Nov: ₹7,146 cr 🟩 11th Nov: ₹12,563 cr 🟩 9th Nov: ₹7212 cr 🟩 6th Nov: ₹13,749 cr 🟩 5th Nov: ₹14,974 cr 🟩 4th Nov: +7,284Cr 🟩 3rd Nov: +6836 Cr 🟩 2nd Nov: +3114 Cr 🟩 30th October: +3598 Cr 🟩 DIIs Sold Approx 52,000 Cr
8
16
1
206
16,335
Jayesh Thaker retweeted
BREAKING: Nifty50 profit growth hit 27% in Sep quarter, Highest in 17 quarters, since Jun 2022. Higher than Motilal Oswal's estimate of 24%
8
17
185
5,848
Jayesh Thaker retweeted
Macquarie on Divi's Laboratories - Don't miss the forest for the trees Valuation concerns overblown, in our view: Valuation remains the key investor concern. However, we believe forward multiples are optically elevated as consensus earnings continue to catch up. On our FY29E, Divi’s trades at 40x P/E and 30x EV/EBITDA, which we see as broadly reasonable versus Indian peers (41x and 25x). We forecast FY26-29 revenue, EBITDA and PAT CAGRs of 27%, 44% and 42% for Divi's. While Divi’s management did not quantify its peptide SPPS capacity, it indicated the ongoing expansion could position the company among the top three global peptide manufacturers by capacity We estimate this would require at least ~60kL of SPPS capacity. At full utilisation, we estimate this could generate ~US$1.5bn of revenue and US$550m+ of PAT, equivalent to ~2x FY26 PAT #divis
14
38
3
328
36,729
Jayesh Thaker retweeted
I told you, the October export numbers will surprise you! And our ‘outlook’ looks strong! 😉
86
565
46
4,170
85,248
Some heartening takeaways from the Oct trade data: -Goods exports up 45%; goods imports up only 16.5% -Clearly goods exports are higher because of volume growth not just higher prices; if it was prices, it would have shown up as strong goods import growth -Goods Trade deficit DOWN 6.3% yoy -For the record, goods exports at $49.47 bn is highest ever monthly tally 1/3
46
301
30
1,681
160,576
Jayesh Thaker retweeted
Net direct tax collections reached ₹14.42 lakh crore by November 10, 2026, up 11.76% from last year, covering about 53% of the full-year budget target of ₹26.97 lakh crore. Gross collections grew 14.02% to ₹17.50 lakh crore, but higher refunds of ₹3.08 lakh crore moderated the net gain. Corporate taxes led with 17.8% growth to ₹6.32 lakh crore, while non-corporate taxes rose 5.3% to ₹7.56 lakh crore, and securities transaction tax jumped 51% amid market activity. Analysts see robust corporate performance but note slower non-corporate growth as the government targets 15% annual expansion. 1. STT growing at 51% ....killing the Golden Goose by regularly hiking STT . Two years of no returns for investors and huge losses to traders, but govt makes 51% higher tax 2. Corporate taxes lower than personal income tax. Something is not correct when non corporates are paying more tax than firms. 3. Personal income tax growth is slowing at 5.3%. Inflation high, wage growth slow is the obvious inference. 4. Dont have data on STCG/LTCG here, so cant comment on that. 5. Corporate tax growing at 17.8% is pointing to robust earnings growth which is a positive for the markets. 6. Refunds are higher by 25%, these could be for multiple years. 7. Budget target was 15% . Gross collections growth is at 14% and net at 11.76% across the three broad categories. 8. Need to provide more tax relief to Personal income tax payers and capital market tax payers. STT is way too high , will cross Rs 75,000 crores this year at this rate.
Data on Gross Direct Tax Collections, Refunds and Net Direct Tax Collections for FY 2026-27 as on 10.11.2026 has been released. The data is available on the national website of Income Tax Department at the following link: incometaxindia.gov.in/docume…
27
76
3
419
30,643
Jayesh Thaker retweeted
If you had to bet on ONE style for the next 10 years: A: Compounders (Titan, Divis) B: Cyclical plays (Capital goods, infra) C: New-age tech (Zomato, Indiamart) D: PSU rerating (Railways, defence) 🔵 A. 🔵 B. 🔵 C. 🔵 D.
35
4
101
21,216
Jayesh Thaker retweeted
The CDMO Theme: Are We Approaching Peak EBITDA Margins? Indian CDMOs have delivered exceptional earnings growth over the last few quarters. But a closer look at the numbers suggests investors need to be careful about extrapolating current margins. A few things worth highlighting: 1/ Signs of peak EBITDA margins Divi's Laboratories reported ~42.7% EBITDA margins in Q2 FY27, while Laurus Labs reported 34%. These are exceptional numbers, but are they sustainable? The report estimates normalised EBITDA margins closer to: • Divi's: 35–38% • Laurus: 28–31% • Sai Life: 27–30% In other words, current margins could be 300–500 bps above sustainable levels. 2/ Cohance is a warning sign Look at what happened with Cohance Lifesciences. FY26 revenue declined 13% due to customer destocking in two commercial CDMO molecules. Adjusted EBITDA margins collapsed from 33.7% to 21%, a 1,270 bps decline. Interestingly, gross margins actually improved from 68.7% to 70.8%. This tells us something important. CDMO businesses have significant fixed costs. When commercial shipments get deferred or customers reduce inventory, operating leverage works in reverse. Neuland experienced a similar 860 bps EBITDA margin contraction during a quarter of weak commercial shipments. 3/ The next capex cycle could impact profitability Several companies are entering an aggressive capex phase. FY27 capex as a percentage of FY26 revenue: • Sai Life: ~50% • Anthem: 38% • Laurus: 31% • Divi's: 29% • Syngene: 25% • Piramal Pharma: 19% New facilities don't immediately operate at optimal utilisation. Employee costs, maintenance, validation expenses and depreciation start coming in much before the facilities reach full capacity. This could create margin pressure over the next few quarters. Moreover, incremental asset turns are declining. Laurus is targeting ~1.1x compared with 1.4x in FY21, while Blue Jet expects ~2.5x asset turns from its new Vizag facility compared with historical levels above 5x. Higher capex doesn't necessarily translate into proportionately higher returns. 4/ Customer concentration and inventory risk CDMO revenues can be heavily dependent on a handful of commercial molecules. At Divi's, the top five customers accounted for 49% of FY25 revenue, while the top five products contributed 43%. A delay in one major commercial programme, a clinical setback or customer destocking can materially impact quarterly earnings. Also, working capital remains a concern. Divi's had a cash conversion cycle of approximately 175–194 days, with FY26 free cash flow of just ₹218 Cr against net profit of ₹2,568 Cr. Strong accounting earnings don't always translate into equally strong cash generation. 5/ Valuations are probably the biggest risk Look at the valuations highlighted in the November 2026 report: • Divi's: ~91x trailing P/E • Laurus: ~94x • Sai Life: ~89x • Anthem: ~79x • Neuland: ~63x • Syngene: ~56x • Blue Jet: ~45x The Nifty 500, meanwhile, trades at approximately 22x. The problem isn't that these businesses don't deserve a premium. The problem is paying premium multiples when EBITDA margins themselves could be at cyclical highs. Even a 300–500 bps margin correction, combined with multiple compression, can create significant downside. My takeaway: I remain positive on the long-term Indian CDMO opportunity. China+1, BIOSECURE, GLP-1 peptides, complex molecules and increasing outsourcing by global innovators are powerful structural tailwinds. But the industry opportunity and stock valuations are two different things. The next phase will require much better stock selection. I would focus on commercial pipeline conversion, customer diversification, sustainable EBITDA margins, incremental ROCE and free cash flow rather than simply chasing the latest quarterly earnings growth. A great industry doesn't automatically make every stock a great investment at any price. Don't confuse peak earnings with sustainable earnings.
9
6
1
60
7,091
Jayesh Thaker retweeted
ALL-TIME HIGH BREAKOUT ALERT! 🔥 9 stocks broke above their previous all-time highs and closed at record levels today! 🚀 💠ICICI Bank 💠Laurus Labs 💠Ather Energy 💠Sai Life Sciences 💠South Indian Bank 💠Divi's Laboratories 💠Aurobindo Pharma 💠Entero Healthcare Solutions 💠Sona BLW Precision Forgings 09-11-2026
3
17
2
195
19,085
#Gujarat #Ahmedabad #SpaceTech Congrats @RuntimeBRT And lots of wishes too!!! @CMOGuj
🚨 Ahmedabad-based PierSight (@piersightspace) has successfully integrated and tested the structural qualification model of their first commercial SAR + AIS satellite, Varuna 2.0. The company’s long-term goal is to build a 32-satellite constellation for persistent maritime surveillance. This is part of PierSight’s main philosophy of building Synthetic Aperture Radar (SAR) systems tailored to specific applications across sectors such as maritime, Earth observation, and more. Use cases of the Varuna constellation include: - EEZ surveillance - Maritime insurance - Illegal fishing monitoring - Oil spill/dumping detection - ⁠Identifying ship movements and patterns
49
#Dipawali2026 #Ayodhya Jai Shri Ram 🙏🏻
दीपोत्सव से पूर्व प्रकाशमान प्रभु श्रीराम का धाम... 📍अयोध्या जी
25
Jayesh Thaker retweeted
તું લઈ ને આવે લાગણીનો મેળો ❤️🤌🥺>>>>>>>>>>
25
81
8
696
19,857
Divis laboratories aiming to be in world's top 3 largest players in terms of peptides capacity. Source : stockscans.in/concall-scans Disc : Not a buy / sell recommendation.
9
16
390
31,286
Jayesh Thaker retweeted
Divis Laboratories #Divis #DivisLab Solid Q2FY27 with big QoQ and YoY uptick across all parameters Solid margin expansion Highest ever set Rev at 3676cr vs 2715cr⏫35% YoY Q1 at 3080cr⏫19% QoQ Other income at 94cr vs 145cr EBITDA at 1566cr vs 888cr⏫76% YoY Q1 at 1255cr⏫25% QoQ OPM at 42.6% vs 32.7%⏫989 bps Q1 at 40.75% PBT at 1505cr vs 912cr⏫66% YoY Q1 at 1180cr⏫25% QoQ PAT at 1127cr vs 689cr⏫64% YoY Q1 at 902cr⏫25% QoQ OCF at 384cr vs 1645cr
8
17
2
274
34,850
Jayesh Thaker retweeted
And the Emperor delivers! #divis
Dekho woh aa raha hai...!
10
21
4
415
29,913
#TimesofIndia #Dhanteras #Gold @timesofindia Pls chk today’s Ahmedabad edition, Same day two different version on same issue….. which is true?? …’High prices shine off Dhanteras sales’ or …’Decline in gold prices pushes sales on Dhanteras”
24
Jayesh Thaker retweeted
#2QWithCNBCTV18 | #Titan reports its Q2 results; --Net Profit At ₹1,572 Cr Vs CNBC-TV18 Poll Of ₹1,394 Cr --Revenue At ₹17,830 Cr Vs CNBC-TV18 Poll Of ₹19,061 Cr --EBITDA At ₹2,626 Cr Vs CNBC-TV18 Poll Of ₹2,154 Cr --EBITDA Margin At 14.7% Vs CNBC-TV18 Poll Of 11.3%
4
11
1
146
22,045
Jayesh Thaker retweeted
BREAKING: 🇮🇳 India's total market capitalisation hits ₹500 lakh crore for the first time in history
14
237
14
2,109
37,451
#Gujarat #Datacentre #Nifty #Stockmarket Amazing achievement, within just 4 months of launching Data centre policy, Gujarat gets proposal of 24 GW ( Target 7.5 GW ), worth Rs 23 lk cr ( Target 6 lk cr ) @CmoGujarat
💻 ₹23 lakh crore. 24 GW. 27 proposals. Gujarat’s data-centre push gains momentum. Within just four months of announcing its Data Centre Policy 2026–29, Gujarat has received 27 proposals with a combined proposed capacity of around 24 GW. 📍 Dholera leads with 19 proposals ⚡ Proposed capacity: 17 GW 💰 Proposed investment: Over ₹18 lakh crore The state’s policy target is 7.5 GW of data-centre capacity and over ₹6 lakh crore in investment.
2
94
Jayesh Thaker retweeted
$1.5 trillion wealth transfer #ET
4
30
5,652